ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BBOT vs KRRO // RSI-14 & 200D SMA MOMENTUM

BridgeBio Oncology Therapeutics Inc. (NASDAQ) VS. Korro Bio Inc. (NASDAQ) • 15-METRIC TALLY: BBOT 0 — KRRO 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: KRRO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBOT VS. KRRO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BBOT KRRO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 KRRO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 24.1 71.4 -47.30 KRRO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $210.1M $210.8M -$741.0K KRRO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BBOT REV KRRO REV BBOT GROSS % KRRO GROSS % BBOT FCF KRRO FCF
FY 2025 $408.3M $6.4M — — -$114.5M -$79.1M
FY 2024 $226.4M $2.3M — — -$55.1M -$78.0M
FY 2023 $116.7K $236.7M — — — -$67.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBOT // BETA —
KRRO // BETA —